KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBT Margin: 2019-2025

Historic EBT Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -36.66%.

  • Esperion Therapeutics' EBT Margin rose 2359.00% to -36.66% in Q3 2025 from the same period last year, while for Sep 2025 it was -35.47%, marking a year-over-year decrease of 2145.00%. This contributed to the annual value of -1.46% for FY2024, which is 18296.00% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' EBT Margin is -36.66%, which was down 125.56% from -16.25% recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' EBT Margin ranged from a high of 42.29% in Q1 2024 and a low of -1,140.00% during Q1 2021.
  • Over the past 3 years, Esperion Therapeutics' median EBT Margin value was -60.25% (recorded in 2024), while the average stood at -85.66%.
  • Per our database at Business Quant, Esperion Therapeutics' EBT Margin spiked by 313,267bps in 2021 and then crashed by 24,628bps in 2022.
  • Esperion Therapeutics' EBT Margin (Quarterly) stood at -448.40% in 2021, then soared by 14,634bps to -302.06% in 2022, then spiked by 12,400bps to -178.06% in 2023, then spiked by 14,790bps to -30.16% in 2024, then skyrocketed by 2,359bps to -36.66% in 2025.
  • Its EBT Margin was -36.66% in Q3 2025, compared to -16.25% in Q2 2025 and -63.89% in Q1 2025.